Press Release

Biopharma leader brings extensive international leadership experience in portfolio strategy and commercialisation MANCHESTER, UK, PRINCETON, NJ & VIENNA, AUSTRIA –15 September 2021 – F2G Ltd, a clinical-stage biopharmaceutical company focused on rare life-threatening fungal diseases with a high unmet medical need, today announces the appointment of Camilla Soenderby as a Non-Executive Director to its Board of […]

Brings substantial pharmaceutical expertise to lead the development and commercialization of olorofim in the USA Ian Nicholson stepping down to pursue non-executive roles MANCHESTER, UK / VIENNA, AUSTRIA, April 12, 2021 — F2G Limited (“F2G”), a clinical-stage biopharmaceutical company focused on life threatening fungal diseases, announces that Francesco Maria Lavino has been appointed Chief Executive

In Phase 2b development for the treatment of life-threatening fungal infectionsFirst antifungal agent to receive Breakthrough Therapy DesignationNew second Breakthrough Therapy Designation for CNS Valley Fever (coccidioidomycosis) MANCHESTER, UK / VIENNA, Austria – October 22, 2020 – F2G Ltd, a UK- and Austria-based biotech company developing novel therapies for life-threatening systemic fungal infections, announced today that

Financing round led by Cowen Healthcare Investments with strong support from existing investors Novo Holdings, Morningside Ventures, Brace Pharma Capital and Advent Life Sciences MANCHESTER, UK / VIENNA, Austria – 12th August 2020 – F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections, announced today that it has secured US

Olorofim is currently in Phase 2b development for the treatment of life-threatening fungal infections MANCHESTER, UK / VIENNA, Austria – 10 June 2020 – F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections, announced today that following the granting of Breakthrough Therapy designation in November (the first antifungal ever to

Currently in Phase 2b development for the treatment of life-threatening fungal infections MANCHESTER, UK / VIENNA, Austria – 09 March 2020 – F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead

In Phase 2b development for the treatment of life-threatening fungal infections First antifungal agent to receive Breakthrough Therapy designation MANCHESTER, UK / VIENNA, Austria – November 11, 2019 – F2G Ltd, a UK- and Austria-based biotech company developing novel therapies for life-threatening systemic fungal infections, announced today that the US Food and Drug Administration (FDA) has

Brings successful track record of building and growing global businesses MANCHESTER, UK & VIENNA, AUSTRIA – 8 April 2019 – F2G Ltd, the European biotech company developing novel therapies for life-threatening fungal infections, today announces the appointment of Dr Patrick Vink as Chairman of the Board of Directors with immediate effect. Dr Vink replaces Dr Richard

March 28, 2019 The Award is in recognition of F2G’s dedication to the development of novel therapies to treat life-threatening invasive fungal infections in an area of a high unmet medical need. In November 2018 F2G Biotech GmbH Austria received a €24M venture loan from the EIB’s InnovFin Infectious Diseases Finance Facility (IDFF). The EIB

New investor Morningside Venture joins existing blue-chip investor syndicate Company accelerates global phase 2b study of lead candidate olorofim to develop its novel antifungal in an area of high unmet medical need MANCHESTER, UK – 07 January 2019 – F2G Ltd, a UK- and Austria-based Biotech developing novel therapies for life-threatening fungal infections, today announced